The oligonucleotide (oligo) DNA market in Indonesia is in its developmental stages, with increasing efforts to establish local synthesis capabilities. Historically, researchers and institutions in Indonesia have relied heavily on imported oligonucleotides for their molecular biology and genetic research needs.
A significant advancement occurred in 2024 when the Biotechnology Study Center at Gadjah Mada University (UGM), in collaboration with Yayasan Satriabudi Dharma Setia (YSDS) and PT Widya Teknologi Hayati, launched Indonesia’s first oligo production line. This milestone was unveiled during the National Biotechnology Conference organized by UGM in October. The initiative aims to provide high-quality and competitively priced DNA/RNA primers to meet the growing demand within the country. Erlina VF Ratu, a mentor at YSDS, highlighted the importance of this development, stating, “We now have the first oligo synthesizer in Indonesia.”
The establishment of local synthesis facilities is expected to reduce dependence on imports, lower costs, and accelerate research timelines for Indonesian scientists. This development aligns with broader growth trends in the Asia-Pacific region. The Asia-Pacific oligonucleotide synthesis market was valued at USD 2.41 billion in 2023 and is projected to reach USD 8.75 billion by 2031, with a compound annual growth rate (CAGR) of 17.5%.
In summary, while the oligo DNA market in Indonesia is still emerging, this recent initiative to build local synthesis capabilities is set to enhance the country’s biotechnology research infrastructure and reduce reliance on imported oligonucleotides.
